A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

Bahil Ghanim, Mir Alireza Hoda, Thomas Klikovits, B. Döme, Michael Grusch, Martin Filipits, Walter Klepetko, Walter Berger, B. Hegedűs

Research output: Contribution to journalArticle

Abstract

Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.

Original languageEnglish
Pages (from-to)52-56
Number of pages5
JournalMemo - Magazine of European Medical Oncology
Volume8
Issue number1
DOIs
Publication statusPublished - Apr 14 2015

Fingerprint

Biomarkers
Lymph Nodes
Phenotype
Malignant Mesothelioma
Proteins

Keywords

  • Malignant pleural mesothelioma
  • Multimodality therapy
  • Predictive biomarker
  • Prognostic biomarker

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. / Ghanim, Bahil; Hoda, Mir Alireza; Klikovits, Thomas; Döme, B.; Grusch, Michael; Filipits, Martin; Klepetko, Walter; Berger, Walter; Hegedűs, B.

In: Memo - Magazine of European Medical Oncology, Vol. 8, No. 1, 14.04.2015, p. 52-56.

Research output: Contribution to journalArticle

Ghanim, Bahil ; Hoda, Mir Alireza ; Klikovits, Thomas ; Döme, B. ; Grusch, Michael ; Filipits, Martin ; Klepetko, Walter ; Berger, Walter ; Hegedűs, B. / A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma. In: Memo - Magazine of European Medical Oncology. 2015 ; Vol. 8, No. 1. pp. 52-56.
@article{61aa1e900c77404b8cb2e1376c7c7209,
title = "A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma",
abstract = "Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.",
keywords = "Malignant pleural mesothelioma, Multimodality therapy, Predictive biomarker, Prognostic biomarker",
author = "Bahil Ghanim and Hoda, {Mir Alireza} and Thomas Klikovits and B. D{\"o}me and Michael Grusch and Martin Filipits and Walter Klepetko and Walter Berger and B. Hegedűs",
year = "2015",
month = "4",
day = "14",
doi = "10.1007/s12254-014-0166-4",
language = "English",
volume = "8",
pages = "52--56",
journal = "Memo - Magazine of European Medical Oncology",
issn = "1865-5041",
publisher = "Springer Wien",
number = "1",

}

TY - JOUR

T1 - A critical update on prognostic and predictive biomarkers in malignant pleural mesothelioma

AU - Ghanim, Bahil

AU - Hoda, Mir Alireza

AU - Klikovits, Thomas

AU - Döme, B.

AU - Grusch, Michael

AU - Filipits, Martin

AU - Klepetko, Walter

AU - Berger, Walter

AU - Hegedűs, B.

PY - 2015/4/14

Y1 - 2015/4/14

N2 - Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.

AB - Malignant pleural mesothelioma (MPM) is a devastating and treatment-resistant disease. Currently, well-established prognostic and predictive biomarkers are rare in clinical practice, whereas there is a whole body of various MPM biomarker studies published in medical literature in the past decades. Besides well-established pathological parameters, including histological subtype, disease stage, or level of lymph node involvement, blood parameters and circulating proteins related to a proinflammatory phenotype are emerging as prognostic biomarkers. Here we provide an overview about the current status of prognostic and predictive biomarkers in MPM, with a strong emphasis on their applicability in clinical practice.

KW - Malignant pleural mesothelioma

KW - Multimodality therapy

KW - Predictive biomarker

KW - Prognostic biomarker

UR - http://www.scopus.com/inward/record.url?scp=84928236805&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928236805&partnerID=8YFLogxK

U2 - 10.1007/s12254-014-0166-4

DO - 10.1007/s12254-014-0166-4

M3 - Article

AN - SCOPUS:84928236805

VL - 8

SP - 52

EP - 56

JO - Memo - Magazine of European Medical Oncology

JF - Memo - Magazine of European Medical Oncology

SN - 1865-5041

IS - 1

ER -